Get the Stockscreener App
19.39
10.42%
1.83
Pre-market:
18.73
-0.66
-3.40%
Seres Therapeutics Inc stock is traded at $19.39, with a volume of 366.50K.
It is up +10.42% in the last 24 hours and down -0.26% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$17.56
Open:
$17.89
24h Volume:
366.50K
Relative Volume:
2.07
Market Cap:
$169.75M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-969.50
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
+10.11%
1M Performance:
-0.26%
6M Performance:
+35.96%
1Y Performance:
-12.66%
1-Day Range:
$17.10
$19.85
1-Week Range:
$15.81
$19.85
52-Week Range:
$6.53
$24.67
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
19.39 | 153.73M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Seres Cuts Jobs To Fund Next Microbiome Bet As Cash Runs Low - insights.citeline.com
MCRB: Analyst John Newman Raises Price Target to $22 | MCRB Stoc - GuruFocus
Canaccord Genuity raises Seres Therapeutics stock price target to $22 on FDA hopes - Investing.com
Seres Therapeutics price target raised to $22 from $14 at Canaccord - TipRanks
Seres Therapeutics (MCRB) Plans Workforce Reduction to Extend Ca - GuruFocus
Seres Therapeutics (MCRB) Advances with FDA Feedback on SER-155 Study - GuruFocus
Seres Therapeutics advances SER-155 protocol after FDA feedback By Investing.com - Investing.com Australia
Seres Therapeutics advances SER-155 protocol after FDA feedback - Investing.com
Seres Therapeutics to Cut Staff by 25%, Extend Cash Runway - MarketScreener
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway - The Manila Times
Seres Therapeutics Advances SER-155 Phase 2 Study Protocol and Initiates Workforce Reduction to Extend Cash Runway - Quiver Quantitative
Seres Therapeutics announces further constructive feedback from FDA on SER-155 Phase 2 study protocol and implements cost reduction actions to extend cash runway - MarketScreener
25% Workforce Cut: Seres Therapeutics Extends Cash Runway While Advancing Breakthrough Blood Infection Drug - Stock Titan
Seres Therapeutics Inc. stock retracement – recovery analysisMarket Sentiment Review & Free High Return Stock Watch Alerts - newser.com
What indicators show strength in Seres Therapeutics Inc.July 2025 Decliners & Consistent Growth Equity Picks - newser.com
How high can Seres Therapeutics Inc. stock goMarket Performance Recap & Consistent Profit Alerts - newser.com
Developing predictive dashboards with Seres Therapeutics Inc. dataTrade Entry Summary & Weekly High Momentum Picks - newser.com
Combining machine learning predictions for Seres Therapeutics Inc.Buy Signal & Free Accurate Trade Setup Notifications - newser.com
What to expect from Seres Therapeutics Inc. in the next 30 daysJuly 2025 Outlook & AI Powered Trade Plan Recommendations - newser.com
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Technical analysis overview for Seres Therapeutics Inc. stockQuarterly Market Summary & Daily Price Action Insights - newser.com
Is this a good reentry point in Seres Therapeutics Inc.July 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
What earnings revisions data tells us about Seres Therapeutics Inc.Oil Prices & Daily Momentum Trading Reports - newser.com
Revenue Check: What are Flag Ship Acquisition Corporations technical support levelsWeekly Stock Recap & Precise Swing Trade Alerts - khodrobank.com
Aug EndMonth: Is Seres Therapeutics Inc impacted by rising rates2025 Breakouts & Breakdowns & AI Forecast Swing Trade Picks - khodrobank.com
Seres Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:MCRB - Benzinga
Candlestick signals on Seres Therapeutics Inc. stock todayJuly 2025 Price Swings & Verified Entry Point Signals - newser.com
Measuring Seres Therapeutics Inc.’s beta against major indicesPortfolio Profit Report & Weekly Top Performers Watchlists - newser.com
Nasdaq Moves: Can Seres Therapeutics Inc. be the next market leaderJuly 2025 Review & Stock Market Timing Techniques - خودرو بانک
Can swing trading help recover from Seres Therapeutics Inc. lossesDollar Strength & Safe Capital Growth Trade Ideas - newser.com
Risk Analysis: What’s next for Seres Therapeutics Inc. stockWeekly Stock Summary & Verified Trade Idea Suggestions - خودرو بانک
Aug Closing: What are Seres Therapeutics Inc.’s earnings expectationsWeekly Trade Report & Safe Capital Growth Tips - خودرو بانک
Seres Therapeutics Inc. recovery potential after sell offJuly 2025 Spike Watch & Accurate Intraday Trade Tips - newser.com
Understanding Seres Therapeutics Inc.’s price movementEarnings Performance Report & Real-Time Chart Breakout Alerts - newser.com
Short Covering: Why is A0ULJS stock going upPrice Action & Low Risk Entry Point Guides - khodrobank.com
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Is Seres Therapeutics Inc. a candidate for recovery playJuly 2025 Volume & Smart Allocation Stock Reports - newser.com
Intraday pattern recognizer results for Seres Therapeutics Inc.Analyst Downgrade & Weekly Top Gainers Alerts - newser.com
How to monitor Seres Therapeutics Inc. with trend dashboardsJuly 2025 Breakouts & Reliable Volume Spike Alerts - newser.com
Using data tools to time your Seres Therapeutics Inc. exitMarket Performance Report & Daily Market Momentum Tracking - newser.com
Seres Therapeutics soars on report of takeover offer - MSN
Aug Gainers: Is Granite Construction Incorporated showing insider buyingEntry Point & Growth Oriented Trade Recommendations - خودرو بانک
Momentum Shift: Can Seres Therapeutics Inc outperform under higher oil pricesInflation Watch & Technical Pattern Recognition Alerts - خودرو بانک
VIX Spike: Is Seres Therapeutics Inc. backed by strong institutional buying2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Buyout Rumor: What is Janux Therapeutics Inc.’s valuation compared to sectorQuarterly Profit Report & Accurate Intraday Trading Signals - خودرو بانک
What data driven models say about Seres Therapeutics Inc.’s futureGold Moves & Smart Swing Trading Techniques - newser.com
Chart Watch: Is WINA subject to activist investor interestQuarterly Portfolio Review & Free Daily Entry Point Trade Alerts - خودرو بانک
Breakout Watch: Is Seres Therapeutics Inc. backed by strong institutional buyingJuly 2025 Recap & Safe Capital Growth Tips - خودرو بانک
Analyzing net buyer seller activity in Seres Therapeutics Inc.2025 Major Catalysts & Real-Time Sentiment Analysis - newser.com
Fund Flows: Whats Seres Therapeutics Incs historical returnJuly 2025 Snapshot & Pattern Based Trade Signal System - خودرو بانک
Aug Movers: Is Cactus Inc stock heavily shortedJuly 2025 Earnings & Short-Term Swing Trade Alerts - خودرو بانک
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):